Akèy › Limfom Difize Gwo Selil B › Illinois › Chicago
Etid klinik pou Limfom Difize Gwo Selil B nan Chicago, IL
18 etid pou Limfom Difize Gwo Selil B ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Ap rekriteFaz 2
- Northwestern University - Feinberg School of Medicine, Chicago
- Rush University Medical Center, Chicago
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Ap rekriteFaz 2
- Northwestern University, Chicago
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Ap rekriteFaz 2
- University of Chicago Medical Center ( Site 0126), Chicago
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
Ap rekriteFaz 1
- The University of Chicago Medical Center (UCMC), Chicago
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Ap rekriteFaz 1
- University of Chicago Comprehensive Cancer Center, Chicago
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
Ap rekriteFaz 1/2
- University of Chicago, Chicago
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Ap rekriteFaz 1/2
- University of Chicago Medical Center, Chicago
Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU
Ap rekriteEtid obsèvasyon
- Robert H Lurie Cancer Center, Chicago
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Ap rekriteFaz 3
- Northwestern, Chicago
- University of Chicago, Chicago
DALY II USA/ MB-CART2019.1 for DLBCL
Ap rekriteFaz 2
- Robert H Lurie Cancer Center, Chicago
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- University of Illinois at Chicago, Chicago
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Ap rekriteFaz 1
- Northwestern University, Chicago
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- Northwestern University, Chicago
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
Ap rekriteFaz 1/2
- University of Illinois at Chicago Cancer Center, Chicago
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Ap rekriteFaz 1
- The University of Chicago Medical Center, Chicago
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Ap rekriteFaz 2
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Ap rekriteFaz 2
- University of Illinois, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
A Study of NX-1607 in Adults With Advanced Malignancies
Ap rekriteFaz 1
- University of Chicago, Chicago
Etid Limfom Difize Gwo Selil B nan lòt vil
- New York City, NY21 etid
- Baldwin Park, CA19 etid
- Los Angeles, CA17 etid
- Houston, TX17 etid
- Boston, MA16 etid
- Milwaukee, WI16 etid
- Portland, OR15 etid
- Nashville, TN15 etid
- Philadelphia, PA15 etid
- Durham, NC14 etid
- Dallas, TX13 etid
- Seattle, WA12 etid
Lòt etid nan Chicago
- Kansè Poumon ki pa ti selil61 etid
- Kansè nan tete58 etid
- Kansè (tout kalite)51 etid
- Kansè Metastatik45 etid
- Kansè pwostat45 etid
- Obèsite41 etid
- Kansè poumon41 etid
- Kansè ovè36 etid
- Akidan serebavaskilè34 etid
- Kansè kolorektal33 etid
- Ensifizyans kadyak31 etid
- Sipwa28 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 3, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.